Assessment of direct oral anticoagulant assay use in clinical practice.


Journal

Journal of thrombosis and thrombolysis
ISSN: 1573-742X
Titre abrégé: J Thromb Thrombolysis
Pays: Netherlands
ID NLM: 9502018

Informations de publication

Date de publication:
Apr 2019
Historique:
pubmed: 3 1 2019
medline: 23 7 2019
entrez: 3 1 2019
Statut: ppublish

Résumé

There are no clear and consistent guidelines on how to utilize DOAC assays, and reports on the use of DOAC levels in clinical practice is limited. The objective of this study was to analyze why DOAC levels are ordered, how the results affect clinical decision-making, and to determine if DOAC assays are utilized appropriately. This was a retrospective chart review study analyzing 150 dabigatran, rivaroxaban, and apixaban levels performed at a single institution. The majority of DOAC assays were ordered in situations or special patient populations where confirming absence or detecting presence of drug may be useful. The most common indication for ordering assays was prior to an invasive procedure. Most DOAC levels were timed appropriately but peak levels were most likely to be incorrectly ordered. Clinical decisions following level results depended on indication for ordering and were most commonly used to determine whether or not to proceed with an invasive procedure. The results of our study suggest while DOAC assays are generally ordered for useful indications, there is still a lack of understanding of when levels should be drawn and how to interpret DOAC assay results.

Identifiants

pubmed: 30600427
doi: 10.1007/s11239-018-1793-0
pii: 10.1007/s11239-018-1793-0
doi:

Substances chimiques

Anticoagulants 0
Factor Xa Inhibitors 0
Pyrazoles 0
Pyridones 0
apixaban 3Z9Y7UWC1J
Rivaroxaban 9NDF7JZ4M3
Dabigatran I0VM4M70GC

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

403-408

Références

Blood. 2008 Sep 15;112(6):2242-7
pubmed: 18621928
Thromb Haemost. 2008 Sep;100(3):453-61
pubmed: 18766262
Thromb Haemost. 2010 Jun;103(6):1116-27
pubmed: 20352166
Circulation. 2012 Jul 17;126(3):343-8
pubmed: 22700854
Circulation. 2014 May 6;129(18):1850-9
pubmed: 24552831
Blood. 2014 Dec 11;124(25):3692-8
pubmed: 25320240
Thromb Res. 2015 Jul;136(1):7-12
pubmed: 25981138
Am J Med. 2015 Dec;128(12):1300-5.e2
pubmed: 26144101
Hematology Am Soc Hematol Educ Program. 2015;2015:117-24
pubmed: 26637710
J Thromb Haemost. 2016 Mar;14(3):623-7
pubmed: 26911798
J Thromb Haemost. 2016 Jul;14(7):1325-7
pubmed: 27094864
Thromb Res. 2016 Jul;143:40-4
pubmed: 27179131
J Thromb Haemost. 2016 Dec;14(12):2556-2559
pubmed: 27622661
Chest. 2017 Jan;151(1):127-138
pubmed: 27637548
Int J Lab Hematol. 2017 May;39 Suppl 1:31-36
pubmed: 28447413

Auteurs

Tina M Gu (TM)

Department of Pharmacy, University of Washington, 1959 NE Pacific St., EA-146, Seattle, WA, 98195, USA. Tinamg@uw.edu.

David A Garcia (DA)

Division of Hematology, University of Washington, Seattle, WA, USA.

Daniel E Sabath (DE)

Department of Laboratory Medicine, University of Washington, Seattle, WA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH